Ibuprofen 200 mg bioequivalence study

2024-516161-36-00 Protocol 983/24 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 13 Sep 2024 · End 6 Nov 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 983/24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 24
Countries 1
Sites 1

not applicable (submitted trial is BE)

Key facts

Sponsor
Patheon Softgels B.V.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
13 Sep 2024 → 6 Nov 2024
Decision date (initial)
2024-09-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

not applicable (submitted trial is BE)

VersionLevelCodeTermSystem organ class
20.0 PT 10033371 Pain 100000004867

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Patheon Softgels B.V.

Sponsor organisation
Patheon Softgels B.V.
Address
De Posthoornstraat 7
City
Tilburg
Postcode
5048 AS
Country
Netherlands

Scientific contact point

Organisation
Patheon Softgels B.V.
Contact name
Meri

Public contact point

Organisation
Patheon Softgels B.V.
Contact name
Meri

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 24 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
clinical unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-09-13 2024-11-06 2024-09-13 2024-10-16

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-01 Czechia Acceptable
2024-09-10
2024-09-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-11-26 Czechia Acceptable
2024-09-10
2024-11-26